Novel approaches in preclinical HIV vaccine research

Abstract

We review novel HIV envelope immunogen design, including native trimer and germline targeting approaches as well as genetic delivery of broadly neutralizing antibodies and replicating vector vaccinesSUMMARY: Despite 30+ years of research and development, and billions of dollars spent, a well tolerated and effective HIV vaccine remains a public health priority for any chance of ending the AIDS pandemic. It has become very clear that significant investments in novel technologies, innovation, and multidisciplinary science will be necessary to accelerate progress.

Poor Translatability of Biomedical Research Using Animals — A Narrative Review

“…Our understanding of these antibodies, alongside studies on the fine structure of Env and on antibody–virus co-evolution, are important in informing the current and future directions of vaccine design. 232,233 This was reiterated by a 2017 review, ‘Lessons learned from human HIV vaccine trials’, 234 which noted that, while no bNAbs had been induced by any vaccine trials in humans at the time of writing, the detailed analysis of memory B-cell repertoires and the evaluation of antibody effector functions in humans had greatly expanded what could be learned from human trials, with particular regard to antibodies with potential neutralising properties. 234,235 The study of bNAbs in the small percentage of HIV-infected people with elite serum neutralisation has indicated a variety of ways in which bNAb activity may be elicited, and several major bNAb sites have been identified.…”